Cardiovascular

Mitral stenosis: rheumatic disease management and intervention timing

Clinical Overview and When to Suspect Mitral Stenosis

— Commissural fusion + leaflet thickening → ↑ transmitral gradient

— ↑ LA pressure → pulmonary venous congestion → pulmonary HTN → RV failure

— LA dilation → atrial fibrillation and LA thrombus/stroke risk

— Young adult immigrant from Southeast Asia, Africa, or Latin America with progressive dyspnea, hemoptysis, or new AF

— Pregnant patient (28–32 wk) with sudden pulmonary edema and previously "asymptomatic" murmur

— Elderly patient with calcified MAC and exertional dyspnea misattributed to HFpEF

— History of childhood strep pharyngitis, migratory polyarthritis, chorea, or known acute rheumatic fever (ARF)

Board pearl: A young woman with new pulmonary edema after entering the second trimester and an "opening snap" on exam has rheumatic MS until proven otherwise — pregnancy ↑ preload and HR (↓ diastolic filling time), the two things a stenotic mitral valve cannot tolerate. Order TTE before any aggressive diuresis or rate control.

Mitral stenosis (MS) = obstruction to LA→LV diastolic flow, most commonly from rheumatic heart disease (RHD) worldwide; in the US, also consider mitral annular calcification (MAC) in elderly and rare causes (radiation, congenital, carcinoid, SLE, mucopolysaccharidoses).

Normal mitral valve area (MVA) 4–6 cm²; symptoms typically appear when MVA < 1.5 cm² (moderate) and become severe at ≤ 1.5 cm² with elevated gradients, or very severe at ≤ 1.0 cm².

Pathophysiology cascade:

When to suspect on Step 3:

Latent period from ARF to symptomatic MS averages 20–40 years in temperate climates, but is markedly shorter (<10 years) in endemic tropical regions.

Key triggers that unmask previously latent MS: pregnancy, anemia, fever/infection, thyrotoxicosis, new-onset AF with rapid ventricular response, exercise.

Presentation Patterns and Key History

— MVA 1.5–2.5 cm²: asymptomatic or exertional dyspnea only with significant exertion

— MVA 1.0–1.5 cm²: NYHA II–III dyspnea, orthopnea, fatigue, reduced exercise tolerance

— MVA < 1.0 cm²: PND, frank pulmonary edema, hemoptysis, right heart failure signs

— Exertional dyspnea (earliest, from ↑ LA pressure with tachycardia)

— Hemoptysis — from rupture of bronchial-pulmonary venous collaterals ("pulmonary apoplexy")

— Palpitations — onset of AF often precipitates decompensation

— Systemic embolism/stroke — LA thrombus, especially with AF

— Hoarseness (Ortner syndrome) — enlarged LA compresses recurrent laryngeal nerve

— Dysphagia — LA compresses esophagus

— Right heart failure — JVD, ascites, edema in advanced disease with pulmonary HTN

— Country of origin and childhood residence (RHD endemic regions)

— Documented ARF, recurrent strep pharyngitis, Sydenham chorea

— Secondary prophylaxis history: did the patient receive monthly benzathine penicillin G IM?

— Obstetric history; current pregnancy status and gestational age

— Prior valvuloplasty or commissurotomy

— Anticoagulation history and bleeding events

Step 3 management: When a stem describes a 30-year-old immigrant with new-onset palpitations and pulmonary edema, your first three orders are ECG (confirm AF), TTE (confirm and grade MS), and IV rate control with a beta-blocker — NOT immediate cardioversion, because untreated LA thrombus in MS-related AF carries a high stroke risk; obtain TEE before any rhythm control attempt.

Symptom timeline maps to MVA and hemodynamic stress:

Classic symptom set to recognize on a stem:

Critical history elements on Step 3:

Decompensation triggers to ask about: new AF, pregnancy, infection, anemia (especially iron-deficiency in menstruating women), hyperthyroidism, vigorous exercise.

Physical Exam Findings and Hemodynamic Assessment

— Mitral facies — pinkish-purple malar flush from low CO + cutaneous vasodilation (chronic, severe MS)

— Signs of right heart failure: JVD with prominent a wave (or cv wave if TR), hepatomegaly, ascites, peripheral edema

— Tapping apical impulse (palpable S1) — non-displaced; LV is underfilled

— Parasternal heave if RV pressure-loaded from pulmonary HTN

— Palpable P2 in pulmonary HTN

— Loud S1 (leaflets snap shut from a still-open position)

— Opening snap (OS) — early diastolic, high-pitched, after S2

— Low-pitched mid-diastolic rumble at apex, best heard in left lateral decubitus with bell, with presystolic accentuation (lost in AF)

— Shorter A2–OS interval (<70 ms) = higher LA pressure = more severe MS

— Longer rumble duration = more severe MS

— Loud P2, RV heave, Graham Steell murmur (high-pitched diastolic of pulmonary regurgitation) = pulmonary HTN

— Left lateral decubitus + exercise (handgrip, sit-ups) accentuates the rumble

— Expiration brings out left-sided sounds

— ↑ PCWP with prominent a wave; mean transmitral gradient > 5–10 mmHg suggests significant MS

— PA systolic > 50 mmHg at rest or > 60 mmHg with exercise indicates pulmonary HTN — a key intervention trigger

Key distinction: MS rumble vs Austin Flint murmur (severe AR): both are apical diastolic rumbles, but MS has a loud S1 + opening snap, while Austin Flint has a soft S1, no OS, and an accompanying decrescendo diastolic murmur of AR at the LSB. Confusing the two leads to the wrong valve being addressed.

General appearance:

Precordial exam:

Auscultation — the classic triad:

Severity correlates:

Maneuvers:

Hemodynamic assessment when invasive data given:

Diagnostic Workup — Initial Labs, ECG, CXR, Biomarkers

— P mitrale — broad, notched P wave in lead II (>120 ms) and biphasic P in V1 with deep terminal negative deflection → LA enlargement

— Atrial fibrillation — present in ~30–40% of symptomatic MS

— Right axis deviation and RVH (tall R in V1, deep S in V6) with pulmonary HTN

— Straightening of the left heart border (LA appendage fills concavity below pulmonary trunk)

— Double density behind the right heart border (LA enlargement)

— Splaying of the carina (>60°) from LA pushing up the left mainstem bronchus

— Kerley B lines, upper lobe vascular redistribution (cephalization), interstitial edema

— Calcification of the mitral annulus or valve in fluoroscopy

— CBC (anemia worsens symptoms; transfuse cautiously)

— TSH (thyrotoxicosis precipitates AF and decompensation)

— BMP, LFTs (congestive hepatopathy)

— BNP/NT-proBNP — elevated; trends with congestion but less specific than in HFrEF

— ASO/anti-DNase B titers if recent ARF suspected

— Blood cultures × 3 if endocarditis concern

Board pearl: When you see "P mitrale + RAD + RVH" on a Step 3 ECG vignette, mitral stenosis with pulmonary HTN is the answer essentially every time — the combination of left atrial enlargement and right ventricular strain is nearly pathognomonic. Next step is transthoracic echocardiography, not stress testing or cath; you must define valve anatomy before any therapeutic decision.

ECG findings (cheap, high-yield, often the first clue):

Chest X-ray patterns:

Basic labs:

Biomarkers in pregnancy: BNP rises in normal pregnancy but levels > 100 pg/mL warrant TTE.

Diagnostic Workup — Advanced and Confirmatory Studies

— 2D: doming/"hockey stick" deformity of anterior leaflet, restricted posterior leaflet, commissural fusion, leaflet thickening/calcification, LA enlargement, possible thrombus

— Planimetry of MVA at leaflet tips in parasternal short axis (most accurate)

— Pressure half-time (PHT): MVA = 220/PHT (less reliable post-valvuloplasty, with AR, or LV diastolic dysfunction)

— Mean transmitral gradient by continuous-wave Doppler

— PASP estimation from TR jet

— Severe MS: MVA ≤ 1.5 cm² AND/OR diastolic PHT ≥ 150 ms

— Very severe: MVA ≤ 1.0 cm² and PHT ≥ 220 ms

— Mean gradient and PASP are supportive but not primary criteria

— Mandatory before percutaneous mitral balloon valvuloplasty (PMBV) — rules out LA/LAA thrombus, quantifies MR, assesses valve morphology

— Used before cardioversion of MS-associated AF

— Score ≤ 8 → favorable for PMBV

— Score > 8 with significant calcification/MR → favor surgery

Step 3 management: A symptomatic patient with severe MS on TTE proceeds to TEE next to assess valve morphology and exclude LA thrombus — this single test determines whether the patient goes to PMBV vs surgical MVR.

Transthoracic echocardiography (TTE) — the diagnostic gold standard:

Severity grading (ACC/AHA 2020):

Transesophageal echocardiography (TEE):

Wilkins (Abascal) score — 4 criteria scored 1–4 each (leaflet mobility, thickening, calcification, subvalvular thickening):

Exercise stress echo — for symptomatic patients with non-severe MS at rest, or asymptomatic patients with severe MS: assess exertional gradient and PASP.

Cardiac catheterization — reserved for discordant noninvasive data or pre-op CAD evaluation in older patients.

CMR/CT — adjuncts for annular calcification, LAA thrombus when TEE indeterminate.

Risk Stratification and First-Line Management Logic

— Stage A: at risk (mild leaflet doming, normal MVA)

— Stage B: progressive MS (MVA > 1.5 cm², asymptomatic)

— Stage C: asymptomatic severe MS (MVA ≤ 1.5 cm²) — C1 (compensated) vs C2 (decompensated, PASP > 50 mmHg)

— Stage D: symptomatic severe MS

— Symptomatic severe MS (Stage D) with favorable anatomy → PMBV (Class I)

— Asymptomatic severe MS (Stage C) with PASP > 50 mmHg, favorable anatomy → PMBV reasonable (Class IIa)

— Asymptomatic severe MS with new AF → PMBV reasonable (Class IIb)

— Severe MS undergoing other cardiac surgery → concomitant MV surgery

— Symptomatic severe MS with unfavorable anatomy or significant MR → surgical MVR (Class I)

— Slow heart rate → prolong diastole → ↓ LA pressure (β-blockers, non-DHP CCBs, ivabradine)

— Diuretics for pulmonary congestion

— Anticoagulation if AF, prior embolism, or LA thrombus

— Treat triggers: anemia, thyrotoxicosis, infection

— Duration: at least 10 years OR until age 40 if carditis + residual valve disease; longer if high exposure risk

CCS pearl: In a CCS case of decompensated MS in AF with RVR, the correct first three orders are continuous telemetry, IV metoprolol (or diltiazem), and IV furosemide, then TTE and anticoagulation. Cardioversion comes only after TEE clears LA thrombus or 3 weeks of therapeutic anticoagulation.

ACC/AHA staging drives every decision:

Intervention triggers (rheumatic MS):

MAC-related (degenerative) MS is NOT amenable to PMBV — manage medically; surgery is high-risk and reserved for select cases; transcatheter approaches investigational.

Medical management framework — buy time and reduce LA pressure:

Secondary RHD prophylaxis — IM benzathine penicillin G every 4 weeks (every 3 weeks in highest-risk patients):

Pharmacotherapy — First-Line Drug Regimen

— β-blockers (metoprolol succinate 25–200 mg/day, atenolol, bisoprolol) — first line in sinus tachycardia from exertion and in AF

— Non-dihydropyridine CCBs (diltiazem, verapamil) — alternatives when β-blockers contraindicated

— Ivabradine — adjunct in sinus tachycardia if β-blockers insufficient or intolerable; does not work in AF

— Goal resting HR ~60 bpm, exertional HR < 100–110 bpm

— Loop diuretics (furosemide 20–80 mg PO daily) for pulmonary congestion and right heart failure

— Use cautiously — over-diuresis drops preload to a fixed-obstruction valve → hypotension and low CO

— AF (paroxysmal, persistent, or permanent) in moderate–severe rheumatic MS

— Prior embolic event

— LA thrombus on imaging

— Consider with LA diameter > 50 mm and spontaneous echo contrast (Class IIb)

— Warfarin (INR 2–3) is the ONLY guideline-recommended anticoagulant in rheumatic MS with AF or other indications

— DOACs are contraindicated in moderate–severe rheumatic MS (INVICTUS trial: rivaroxaban inferior to warfarin)

— In non-rheumatic (MAC) MS with AF, DOACs are acceptable per CHA₂DS₂-VASc scoring

— Rate control is generally preferred; rhythm control is hard to maintain with enlarged LA

— If cardioversion attempted: anticoagulate ≥ 3 weeks OR perform TEE first; continue anticoagulation indefinitely after

Board pearl: A patient with rheumatic MS and new AF on apixaban should be switched to warfarin — this is the most tested anticoagulation pitfall in valvular heart disease.

Rate control (cornerstone — diastole is the friend of MS):

Diuretics:

Anticoagulation indications in MS:

Choice of anticoagulant — critical Step 3 point:

Rhythm vs rate strategy in AF:

Endocarditis prophylaxis: NOT routinely indicated for MS alone — only for prior IE, prosthetic valve, or certain congenital lesions.

Procedures and Invasive Management

— Indications: symptomatic severe MS (Stage D) OR asymptomatic severe MS with PASP > 50 mmHg, favorable valve morphology

— Favorable anatomy (Wilkins ≤ 8): pliable, non-calcified leaflets, minimal subvalvular fusion, no/mild MR

— Absolute contraindications: LA/LAA thrombus, moderate–severe MR, severe bicommissural calcification, concomitant severe AS or AR needing surgery

— Procedure: trans-septal puncture → Inoue balloon split commissures → typically doubles MVA

— Complications: severe MR (2–10%), residual ASD (usually small, self-limited), tamponade, embolic stroke, conduction block

— Outcomes: 10-year event-free survival 50–80% with favorable anatomy

— Open commissurotomy / mitral valve repair — when PMBV contraindicated and valve repairable

— Mitral valve replacement (MVR) — for heavily calcified, distorted valves, significant MR, or failed PMBV

– Mechanical valve: durable; requires lifelong warfarin (INR 2.5–3.5 mitral position)

– Bioprosthetic valve: no long-term anticoagulation needed (3–6 months warfarin post-op); structural deterioration in 10–15 years

— Concomitant Maze procedure if AF present

— Mitral annular calcification (MAC) MS: surgical risk high; transcatheter mitral valve replacement (TMVR) emerging but investigational

— TEE within 24–48 h pre-PMBV to exclude LAA thrombus

— Hold warfarin to INR < 1.5 (or bridge if very high-risk)

— Coronary angiography in patients > 40 or with CAD risk factors before any open surgery

Step 3 management: A 35-year-old woman with severe rheumatic MS, Wilkins score 7, no MR, no LAA thrombus → PMBV. Same patient with Wilkins 11, calcified valve, and moderate MR → surgical MVR. Pick the procedure that matches valve morphology, not just severity.

Percutaneous mitral balloon valvuloplasty (PMBV) — preferred for favorable rheumatic MS:

Surgical options:

Procedural pre-op essentials:

Special Populations — Elderly and Renal/Hepatic Impairment

— Most US cases are degenerative MAC-related, not rheumatic

— MAC produces a functional MS by restricting annular motion — leaflets themselves often pliable

— TTE may underestimate severity; direct planimetry and invasive gradients often required

— PMBV ineffective for MAC (calcium is annular, not commissural)

— Surgical MVR carries high mortality (5–15%) due to annular calcification, comorbidities

— Medical management is the mainstay: rate control, gentle diuresis, anticoagulation for AF

— TMVR is an emerging option in carefully selected cases at experienced centers

— Accelerated MAC and valvular calcification

— Warfarin in ESRD + AF: controversial — bleeding risk high, calciphylaxis risk; weigh against stroke risk; apixaban acceptable in non-rheumatic MS with ESRD

— Diuretic dosing: higher loop diuretic doses needed; risk of intradialytic hypotension with stenotic valve

— Contrast-induced AKI risk during cath/PMBV — minimize contrast, pre-hydrate

— Congestive hepatopathy from right heart failure can confound LFT interpretation

— Warfarin dosing reduced; monitor INR more frequently

— Avoid hepatotoxic agents; amiodarone (sometimes used for AF) requires LFT monitoring

Key distinction: Elderly + apical diastolic rumble + heavy mitral annular calcification on TTE = degenerative (MAC) MS, not rheumatic — PMBV is contraindicated, medical therapy and rate control dominate. Misclassifying this patient as rheumatic and sending them to valvuloplasty is a frequently tested Step 3 error.

Elderly patients (>70 years):

CKD/ESRD considerations:

Hepatic impairment:

Anesthetic risk in elderly: fixed obstruction means poor tolerance of hypotension; maintain preload, avoid tachycardia, avoid pulmonary HTN-worsening events (hypoxia, hypercarbia, acidosis).

Special Populations — Pregnancy

— Plasma volume ↑ 40–50% by 20–24 weeks → ↑ LA pressure

— HR ↑ 15–20 bpm → ↓ diastolic filling time

— Decompensation peak: late 2nd / early 3rd trimester and peripartum

— Severe MS (MVA < 1.5 cm²) should ideally be treated before conception (PMBV if anatomy favorable)

— mWHO class IV lesions (severe symptomatic MS, severe pulmonary HTN) → pregnancy contraindicated; counsel against

— Discuss anticoagulation strategy if mechanical valve in place

— β-blockers (metoprolol or bisoprolol) — first line; atenolol relatively avoided (IUGR association)

— Diuretics — furosemide for pulmonary congestion; avoid over-diuresis (uteroplacental hypoperfusion)

— Bed rest, salt restriction, treat anemia aggressively

— PMBV during pregnancy — feasible in 2nd trimester for refractory symptoms, with abdominal lead shielding

— Avoid ACEi/ARBs (teratogenic); avoid warfarin in 1st trimester and near delivery if possible

— 1st trimester (weeks 6–12): switch warfarin → LMWH (or UFH) to avoid warfarin embryopathy, especially if warfarin dose > 5 mg

— Weeks 13–36: warfarin acceptable (lowest fetal risk)

— Near delivery (≥ 36 wk): switch to UFH/LMWH; stop before delivery

— Vaginal delivery preferred with assisted second stage (forceps/vacuum) to avoid Valsalva-induced tachycardia

— Epidural anesthesia helpful (reduces pain-driven tachycardia); careful with preload drops

— Continuous monitoring; cardiology + MFM + anesthesia coordination

Board pearl: A pregnant woman at 28 weeks with rheumatic MS who develops pulmonary edema unresponsive to β-blocker + diuretic should undergo PMBV during pregnancy, not emergent MVR — bypass surgery carries 20–30% fetal mortality.

Why pregnancy unmasks MS:

Pre-conception counseling — Step 3 favorite:

Management of MS during pregnancy:

Anticoagulation in pregnant patient with MS + AF or mechanical MV:

Labor and delivery:

Complications and Adverse Outcomes

— Occurs in 30–40% of symptomatic MS, > 70% in severe disease

— Loss of atrial kick + rapid rate → acute pulmonary edema

— Marker of progression; trigger for anticoagulation regardless of CHA₂DS₂-VASc score in rheumatic MS

— LA/LAA thrombus from stasis; risk amplified by AF

— Stroke risk in MS + AF is among the highest of any cardiovascular condition

— Systemic emboli to mesenteric, renal, peripheral circulation

— Initially passive (reactive to ↑ LA pressure), then fixed pulmonary vasoconstriction and remodeling

— Leads to TR, RV dilation, hepatic congestion, ascites

— Post-PMBV: severe MR (2–10%, may need urgent surgery), iatrogenic ASD, restenosis (10-year rate 30–40%)

— Post-MVR: prosthetic valve thrombosis, endocarditis, paravalvular leak, anticoagulation-related bleeding, structural deterioration (bioprosthetic)

Step 3 management: A patient post-PMBV who develops new acute dyspnea, a holosystolic apical murmur, and hypotension has acute severe MR from leaflet tear — emergent TEE and urgent surgical MVR. Do not delay with medical therapy alone.

Atrial fibrillation (most common):

Thromboembolism and stroke:

Pulmonary hypertension and right heart failure:

Hemoptysis ("pulmonary apoplexy"): rupture of dilated bronchial veins under high LA pressure; usually self-limited but alarming

Infective endocarditis: less common than in regurgitant lesions, but risk persists

Recurrent rheumatic fever: in patients off secondary prophylaxis — accelerates valve damage

Procedural complications:

Ortner syndrome: hoarseness from left recurrent laryngeal nerve compression by enlarged LA

Dysphagia: LA compresses esophagus

Death: untreated severe symptomatic MS — 10-year survival < 15%; with intervention, > 80%

When to Escalate Care — ICU, Consult, Inpatient Triage

— Acute pulmonary edema requiring noninvasive or invasive ventilation

— New AF with RVR and hemodynamic instability

— Hypotension or cardiogenic shock from low CO

— Acute severe MR post-PMBV

— Suspected LA thrombus with embolic stroke in evolution

— Massive hemoptysis

— Symptomatic severe MS (Stage D) for diuresis, rate control, TEE planning

— New AF in MS, hemodynamically stable but needing anticoagulation initiation and rate control titration

— Pre-procedural admission for PMBV or MVR

— Asymptomatic Stage B or C1 patients with stable HR, no AF

— Established medical regimen, no congestion

— Routine TTE follow-up cadence (see chunk 16)

— Cardiology — all symptomatic or severe MS

— Interventional/structural cardiology — for PMBV evaluation

— Cardiothoracic surgery — when valve unfavorable for PMBV

— Maternal-fetal medicine + cardio-obstetrics — for any pregnant patient with MS

— Cardiac anesthesia — pre-op planning, given fixed obstruction physiology

— Heart Valve Team (multidisciplinary) — required for intervention decisions per ACC/AHA

CCS pearl: In a CCS case of MS with acute pulmonary edema, the simultaneous correct orders are oxygen, IV furosemide, IV β-blocker for rate control, continuous monitoring, cardiology consult, and TTE — then advance the clock and order TEE before any cardioversion or PMBV planning.

Immediate ICU/CCU admission criteria:

Floor admission:

Outpatient (ambulatory) management — Step 3 emphasis:

Required consultations:

Transfer to tertiary center: any patient who is a PMBV or surgical candidate, especially if local volume is low (volume-outcome relationship is strong for valve interventions).

Key Differentials — Same-Category (Valvular) Causes

— Austin Flint murmur (severe AR): apical diastolic rumble from regurgitant jet hitting anterior mitral leaflet; no OS, soft S1, plus AR decrescendo at LSB

— Left atrial myxoma: "tumor plop" mimics OS; positional symptoms, constitutional symptoms (fever, weight loss, ↑ ESR), embolic events; TTE/TEE diagnoses

— Cor triatriatum: congenital membrane in LA — rare; presents in children/young adults with MS-like physiology

— Severe MR with functional MS physiology: high flow across mitral valve in diastole creates a flow rumble; differentiate by dominant systolic murmur and TTE

— Tricuspid stenosis: diastolic rumble at left lower sternal border, increases with inspiration (Carvallo sign); often coexists with MS in RHD

— Prosthetic mitral valve dysfunction: stenosis from pannus or thrombus; recognize by prior valve replacement history

— RHD typically affects valves in order of frequency: mitral > aortic > tricuspid > pulmonic

— Mixed mitral disease (MS + MR) is common in RHD; pure MS less common

— Aortic involvement coexists in ~40% — listen for AR decrescendo and AS systolic murmur

— MAC: elderly, CKD, hyperparathyroidism, prior radiation

— Carcinoid: right-sided lesions predominate, but left-sided possible with patent foramen ovale or pulmonary metastases

— SLE (Libman-Sacks): usually causes MR, but verrucous lesions can produce stenosis

— Congenital MS: parachute mitral valve, supravalvular ring — pediatric presentation

Key distinction: OS + loud S1 = rheumatic MS; tumor plop + positional symptoms + constitutional = LA myxoma; soft S1, no OS, AR murmur = Austin Flint. These three account for nearly all "apical diastolic rumble" stems on Step 3.

Other causes of diastolic apical murmur or mimics of MS:

Differentiating features in rheumatic disease:

Etiology-specific clues:

Key Differentials — Other-Category Causes of Dyspnea/Pulmonary Congestion

— Elderly, hypertensive, diabetic; no OS, no mid-diastolic rumble

— TTE: preserved EF, ↑ E/e′, LA enlargement, no commissural fusion

— Critically: HFpEF and MAC-MS coexist often in elderly — TTE distinguishes

— Group 1 PAH: connective tissue disease, HIV, drugs, idiopathic

— Group 3: COPD, ILD

— Group 4: chronic thromboembolic PH

— All cause exertional dyspnea + RV failure but without mitral inflow obstruction on TTE

— Acute dyspnea, pleuritic chest pain, hemoptysis

— Diagnosed by CTPA; D-dimer, Wells score

— Hemoptysis in MS is venous (chronic); PE hemoptysis is infarction-related

Board pearl: When a young immigrant presents with hemoptysis, always think TB and rheumatic MS together — both endemic, both cause hemoptysis. Order CXR, TTE, and sputum AFB; do not anchor on one diagnosis. Misattributing MS hemoptysis to TB delays valve intervention.

MS often presents as unexplained exertional dyspnea, hemoptysis, or AF — broaden the differential when the exam isn't classic:

Heart failure with preserved ejection fraction (HFpEF):

Pulmonary hypertension (primary or other secondary):

Pulmonary embolism:

COPD/asthma exacerbation: wheezing dominates; MS doesn't wheeze unless severe pulmonary edema causes "cardiac asthma"

Anemia (especially iron-deficiency): high-output state worsens any MS — always check CBC

Hyperthyroidism: AF, tachycardia, heat intolerance — can decompensate previously asymptomatic MS

Pneumonia: fever, productive cough, focal CXR findings

Interstitial lung disease: crackles + restrictive PFTs, no OS

Anxiety/deconditioning: diagnosis of exclusion after cardiac workup

Constrictive pericarditis: elevated JVP with Kussmaul sign, pericardial knock (not OS), calcified pericardium on imaging

Secondary Prevention / Discharge Medications / Long-Term Plan

— Benzathine penicillin G 1.2 million units IM every 4 weeks (every 3 weeks in highest-risk settings)

— Alternatives: penicillin V 250 mg PO BID, sulfadiazine, or macrolides if penicillin-allergic

— Duration:

– ARF without carditis: 5 years or until age 21 (whichever longer)

– ARF with carditis, no residual valve disease: 10 years or until age 21

– ARF with carditis and residual valve disease (including MS): 10 years or until age 40, sometimes lifelong

— Warfarin for AF, prior embolism, LA thrombus in rheumatic MS — lifelong

— Mechanical mitral valve: warfarin INR 2.5–3.5 + low-dose aspirin (controversial; recent guidelines de-emphasize aspirin if no other indication)

— Bioprosthetic valve: warfarin 3–6 months post-op, then aspirin alone if no AF

— Diuretics titrated to euvolemia

— β-blockers continued for rate control

— ACEi/ARB/MRA reserved for coexisting LV dysfunction

— Routine antibiotic prophylaxis NOT indicated for native-valve MS

— Required for prosthetic valves, prior IE, certain congenital lesions — before dental and select procedures

— Excellent oral hygiene, dental visits twice yearly

Step 3 management: Discharge medications for a 28-year-old s/p PMBV with persistent AF: warfarin (INR 2–3), metoprolol succinate, furosemide PRN, monthly IM benzathine penicillin G, influenza vaccine — and structured cardiology follow-up in 2–4 weeks.

Secondary rheumatic fever prophylaxis (critical, frequently tested):

Anticoagulation continuation:

Heart failure-directed medical therapy:

Vaccinations — annual influenza, pneumococcal series, COVID-19, RSV (age-appropriate)

Endocarditis prevention:

Counsel against: strenuous isometric exercise, dehydration, untreated anemia, recreational stimulants

Lifestyle: sodium restriction (<2 g/day), aerobic activity as tolerated, avoid pregnancy if severe untreated MS

Follow-Up, Monitoring, and Rehab/Counseling

— Mild MS (MVA > 1.5 cm², asymptomatic): every 3–5 years

— Moderate MS (MVA 1.0–1.5 cm²): every 1–2 years

— Severe MS (MVA ≤ 1.5 cm² per current grading, asymptomatic): annually

— Any change in symptoms → repeat TTE regardless of interval

— Clinical + TTE at 1 month, 6 months, then annually

— Watch for restenosis (~10–15% at 5 years, 30–40% at 10 years), new/worsened MR, ASD shunt

— Baseline TTE at 4–6 weeks post-op (new reference study)

— Annual clinical visit + TTE; sooner if symptoms or new murmur

— INR monitoring per institution (weekly initially → monthly when stable for mechanical valves)

— Periodic ECG; consider Holter or wearable if suspected paroxysmal AF

— Rate goal 60–80 resting, <110 with moderate exertion

— 6-minute walk test or exercise stress echo for ambiguous symptom-severity mismatch

— Indicated post-valve intervention to optimize functional capacity and adherence

— Supervised programs improve outcomes after valve surgery

— Recognize decompensation: worsening dyspnea, orthopedic, palpitations, hemoptysis, syncope

— Anticoagulation education: bleeding signs, drug-drug interactions, dietary vitamin K consistency for warfarin

— Contraception counseling if pregnancy contraindicated; preconception planning if pregnancy desired

— Adherence to penicillin prophylaxis — the #1 modifiable factor in long-term outcome

— Smoking cessation, weight management

Board pearl: Annual TTE for asymptomatic severe MS and TTE on any symptom change — this is the most tested surveillance interval. Patients lost to follow-up present with new AF and pulmonary edema; structured ambulatory cardiology follow-up prevents this.

TTE surveillance cadence (ACC/AHA):

Post-PMBV follow-up:

Post-MVR follow-up:

AF monitoring:

Functional assessment:

Cardiac rehabilitation:

Counseling priorities:

Ethical, Legal, and Patient Safety Considerations

— Patients must understand procedural alternatives, restenosis risk, anticoagulation implications of mechanical vs bioprosthetic valves

— Shared decision-making documented, especially for younger women considering future pregnancy (bioprosthetic avoids warfarin teratogenicity but has shorter durability)

— Discharge with warfarin requires explicit INR follow-up plan within 3–5 days, anticoagulation clinic enrollment

— Medication reconciliation: warfarin interactions with antibiotics (especially TMP-SMX, metronidazole, fluoroquinolones), amiodarone, NSAIDs

— Counsel against DOAC substitution by other providers — common error in rheumatic MS

— Post-cardioversion patients must understand the need for continued anticoagulation ≥ 4 weeks even if sinus restored

— Discharge after PMBV: ensure follow-up TTE scheduled before discharge

— Counsel pre-conception about maternal mortality in severe MS (up to 5% in mWHO IV)

— Respect patient autonomy if patient chooses to conceive despite risk; document discussion, optimize care

— Contraception counseling: avoid estrogen-containing methods in patients with AF or prior embolism

— RHD is reportable in some jurisdictions; ARF should be reported to public health for contact tracing of streptococcal disease

— Recurrent strep pharyngitis outbreaks in households/schools warrant intervention

— RHD disproportionately affects immigrants, low-SES, and Indigenous populations

— Ensure access to penicillin prophylaxis (no-cost programs exist), interpreter services, and structural valve centers regardless of insurance

Step 3 management: A patient with rheumatic MS and AF is discharged on apixaban by the covering hospitalist. The correct patient-safety action is to call the patient, switch to warfarin, arrange anticoagulation clinic follow-up within 3 days, and file a safety event report — DOACs are contraindicated and represent a recognized prescribing pitfall.

Informed consent for PMBV vs MVR — multidisciplinary heart team:

Anticoagulation safety — high-risk transition:

Transitions of care risk:

Pregnancy and reproductive ethics:

Mandatory reporting and public health:

Health equity:

High-Yield Associations and Rapid-Fire Clinical Facts

— Major: Joint (migratory polyarthritis), ♥ (carditis), Nodules (subcutaneous), Erythema marginatum, Sydenham chorea

— Need 2 major OR 1 major + 2 minor + evidence of preceding GAS infection

Board pearl: Three "MS pearls" that crack most stems: (1) opening snap + loud S1 with diastolic rumble = MS; (2) new AF + pulmonary edema in young immigrant = decompensated rheumatic MS — anticoagulate with warfarin; (3) Wilkins ≤ 8 + no LA thrombus → PMBV.

Rheumatic fever Jones criteria reminders (the cause):

Severity grading shortcut: Severe MS = MVA ≤ 1.5 cm² OR PHT ≥ 150 ms

A2–OS interval inversely correlates with severity (shorter = worse)

P mitrale: notched P > 120 ms in lead II; biphasic P in V1 with deep terminal negative deflection

Wilkins score components (4 each, max 16): mobility, thickening, calcification, subvalvular thickening; ≤ 8 = favorable for PMBV

Ortner syndrome = hoarseness from LA compression of left recurrent laryngeal nerve

Anticoagulation rule: rheumatic MS + AF → warfarin only (not DOAC)

Endocarditis prophylaxis is NOT indicated for native-valve MS

Pregnancy decompensation peaks in late 2nd / early 3rd trimester; β-blockers + diuretics are mainstay; PMBV feasible in 2nd trimester

Order of rheumatic valve involvement: mitral > aortic > tricuspid > pulmonic

MAC-related MS: degenerative, elderly, PMBV contraindicated, manage medically

Hemoptysis cause in MS: rupture of bronchopulmonary venous collaterals

Atrial fibrillation in MS: indication for lifelong warfarin regardless of CHA₂DS₂-VASc

Mitral facies: pink-purple malar flush, severe chronic MS

Tapping apical impulse = palpable loud S1

Graham Steell murmur: PR murmur from severe pulmonary HTN — high-pitched diastolic at LUSB

Secondary penicillin prophylaxis duration: with carditis + residual valve disease → until age 40 or 10 years (whichever longer)

Mechanical mitral valve INR target: 2.5–3.5; bioprosthetic mitral: 3–6 months warfarin then aspirin

Board Question Stem Patterns

"A 26-year-old woman from Sri Lanka presents with progressive dyspnea and palpitations. Exam: loud S1, opening snap, mid-diastolic rumble at apex. ECG: AF with rapid ventricular response."

→ Next step: rate control with β-blocker + anticoagulation with warfarin; then TTE → TEE → PMBV if anatomy favorable.

"A 28-year-old at 30 weeks gestation presents with acute pulmonary edema. Previously asymptomatic. History of rheumatic fever at age 10."

→ Initiate β-blocker + furosemide, urgent TTE; if severe MS + refractory symptoms → PMBV in 2nd trimester (with shielding).

"Patient with rheumatic MS + AF on apixaban. Asks if regimen is appropriate."

→ Switch to warfarin (INR 2–3). DOACs contraindicated in rheumatic MS.

"82-year-old with CKD, hypertension; TTE shows heavy MAC, MVA 1.2 cm², gradient 8 mmHg."

→ Medical therapy, NOT PMBV; rate control, gentle diuresis, anticoagulation if AF (DOAC acceptable in non-rheumatic MAC-MS).

"Day 1 post-PMBV: new holosystolic murmur at apex, hypotension, pulmonary edema."

→ Acute severe MR from leaflet tear → emergent TEE, urgent surgical MVR.

"Apical diastolic rumble with soft S1 and decrescendo diastolic murmur at LSB."

→ Austin Flint (severe AR), NOT MS.

"16-year-old s/p ARF with carditis and residual MS asks how long to continue penicillin shots."

→ Until age 40 or 10 years post-ARF, whichever longer.

"Notched P wave in II, biphasic P in V1 with deep terminal negative deflection, right axis deviation."

→ LAE + RVH = MS with pulmonary HTN → order TTE.

Step 3 management: Recognize these eight stem patterns and you'll capture the majority of MS questions on the exam. The most common right answer is "TTE next" or "warfarin for anticoagulation."

Stem 1 — The young immigrant:

Stem 2 — Decompensation in pregnancy:

Stem 3 — Anticoagulation pitfall:

Stem 4 — Elderly with calcified valve:

Stem 5 — Post-PMBV complication:

Stem 6 — Murmur differential:

Stem 7 — Secondary prophylaxis:

Stem 8 — ECG pattern:

One-Line Recap

Rheumatic mitral stenosis is a fixed obstructive valvulopathy whose management hinges on three decisions: control heart rate to preserve diastolic filling, anticoagulate with warfarin (not DOAC) when AF or thrombus is present, and intervene with percutaneous mitral balloon valvuloplasty in favorable anatomy or surgical replacement when not — while never forgetting monthly benzathine penicillin G to prevent recurrent rheumatic fever.

Board pearl: If you remember one thing — rheumatic MS + AF = warfarin + PMBV evaluation + lifelong penicillin — you will answer most Step 3 MS questions correctly.

Diagnostic anchor: opening snap + loud S1 + apical diastolic rumble + P mitrale + LAE → confirm with TTE (MVA ≤ 1.5 cm² = severe); TEE before any intervention to exclude LAA thrombus.

Pharmacologic anchor: β-blocker for rate control + loop diuretic for congestion + warfarin (INR 2–3) for AF, prior embolism, or LA thrombus in rheumatic MS; DOACs are contraindicated. Continue secondary penicillin prophylaxis until age 40 or 10 years post-ARF with carditis + residual valve disease.

Intervention anchor: PMBV for symptomatic severe MS (Stage D) or asymptomatic severe MS with PASP > 50 mmHg + Wilkins ≤ 8, no significant MR, no LAA thrombus; surgical MVR for unfavorable anatomy, heavy calcification, or significant MR. MAC-related MS is not a PMBV candidate.

Special-population anchor: Pregnant patients decompensate in late 2nd/early 3rd trimester — β-blockers + diuretics first, PMBV in 2nd trimester if refractory; preconception PMBV is ideal in severe MS. Elderly with MAC-MS → medical management dominates.